Phio Pharmaceuticals Corp.
PHIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $6 | $7 | $9 |
| Gross Profit | -$4 | -$6 | -$7 | -$9 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $6 | $7 | $9 |
| G&A Expenses | $4 | $4 | $4 | $5 |
| SG&A Expenses | $4 | $4 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4 | -$6 | -$7 | -$9 |
| Operating Expenses | $4 | $4 | $4 | $5 |
| Operating Income | -$7 | -$11 | -$11 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$7 | -$11 | -$11 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$11 | -$11 | -$13 |
| % Margin | – | – | – | – |
| EPS | -0.91 | -46.87 | -89.61 | -111.32 |
| % Growth | 98.1% | 47.7% | 19.5% | – |
| EPS Diluted | -0.91 | -46.76 | -89.61 | -111.32 |
| Weighted Avg Shares Out | 8 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 8 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$11 | -$11 | -$13 |
| % Margin | – | – | – | – |